<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03959072</url>
  </required_header>
  <id_info>
    <org_study_id>104-08553</org_study_id>
    <nct_id>NCT03959072</nct_id>
  </id_info>
  <brief_title>Cardiac Cath Lab Staff Radiation Exposure</brief_title>
  <acronym>SAFE-T</acronym>
  <official_title>Cardiac Cath Lab Staff Radiation Exposure During Chronic Total Occlusion PCI: CorPath GRX vs. Manual</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corindus Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corindus Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this randomized safety and observational study is to demonstrate CorPath GRX
      chronic total occlusion PCI is safe, and that Cardiac Catheterization Laboratory staff have
      no additional exposure to radiation when compared to conventional manual chronic total
      occlusion PCI procedures without added procedure time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is prospective, dual-arm, randomized, multi-center, observational study comparing
      patient outcomes and staff radiation exposure in chronic total occlusion PCI procedures
      through 48 hours post procedure or hospital discharge, whichever occurs first.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>48 hours</time_frame>
    <description>Defined as successful CTO PCI revascularization with achievement of &lt;30% residual diameter stenosis (visual estimate) within the treated segment and restoration of antegrade TIMI grade 3 flow, without in-hospital major adverse events (MAE).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In-hospital Major Adverse Events (MAE)</measure>
    <time_frame>48 hours</time_frame>
    <description>Number of MAE events that occurs within 48 hours of the CTO PCI procedure or hospital discharge, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Operator Radiation Exposure</measure>
    <time_frame>Procedure</time_frame>
    <description>Cumulative dose the physician receives as recorded from electronic pocket dosimeter during procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Staff Radiation Exposure</measure>
    <time_frame>Procedure</time_frame>
    <description>Cumulative dose the staff receives as recorded from electronic pocket dosemeter during procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Radiation Exposure</measure>
    <time_frame>Procedure</time_frame>
    <description>DAP (dose-area-product) and cumulative dose/air kerma as recorded during the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy Time</measure>
    <time_frame>Procedure</time_frame>
    <description>Total fluoroscopy (min.) utilized during the procedure as recorded by an Imaging System.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Chronic Total Occlusion of Coronary Artery</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Robotic Chronic Total Occlusion PCI</arm_group_label>
    <description>The procedure will be randomized in a 1:1 fashion to either CorPath GRX robotic-assisted Chronic Total Occlusion PCI or conventional manual Chronic Total Occlusion PCI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional (manual) Chronic Total Occlusion PCI</arm_group_label>
    <description>The procedure will be randomized in a 1:1 fashion to either CorPath GRX robotic-assisted Chronic Total Occlusion PCI or conventional manual Chronic Total Occlusion PCI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Robotic CTO PCI</intervention_name>
    <description>Randomized to robotic CTO PCI.</description>
    <arm_group_label>Robotic Chronic Total Occlusion PCI</arm_group_label>
    <other_name>CorPath GRX System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional (Manual) CTO PCI</intervention_name>
    <description>Randomized to manual CTO PCI.</description>
    <arm_group_label>Conventional (manual) Chronic Total Occlusion PCI</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects &gt;18 years of age with symptoms suggestive of ischemic heart disease, with TIMI
        grade 0 flow and a lesion that is thought to be present for more than 3 months.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CTO lesion, successfully crossed with conventional manual techniques;

          -  The Investigator deems the procedure appropriate for robotic-assisted CTO PCI with the
             CorPath GRX System;

          -  Individual monitoring of radiation dose, using the pocket dosimeter, was initiated at
             start of procedure;

          -  The subject has been informed of the nature of the study, agrees to its provisions and
             has provided written informed consent.

        Exclusion Criteria:

          -  Failure/inability/unwillingness to provide informed consent, or

          -  Cardiogenic Shock; or

          -  Perforation which requires treatment (e.g. covered stent, coil and other embolization
             techniques, or pericardiocentesis).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>William Lombardi (Acting), MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Nicholson (Emeritus), MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>WellSpan York Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tina M. Ridgeway, BS, RN</last_name>
    <phone>(757) 810-5166</phone>
    <email>tina.ridgeway@corindus.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John Van Vleet, MS</last_name>
    <phone>(260) 615-8892</phone>
    <email>john.vanvleet@corindus.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Luke's Hospital of Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosann Gans, RN</last_name>
      <phone>816-932-6122</phone>
      <email>rgans@saint-lukes.org</email>
    </contact>
    <investigator>
      <last_name>Adam Salisbury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WellSpan York Hospital</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elayne Grimm</last_name>
      <phone>717-851-3264</phone>
      <email>egrim@wellspan.org</email>
    </contact>
    <investigator>
      <last_name>William J Nicholson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kamilah Taylor</last_name>
      <phone>206-221-2142</phone>
      <email>kit2@cardiology.washington.edu</email>
    </contact>
    <investigator>
      <last_name>William Lombardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hirshfeld JW Jr, Balter S, Brinker JA, Kern MJ, Klein LW, Lindsay BD, Tommaso CL, Tracy CM, Wagner LK, Creager MA, Elnicki M, Lorell BH, Rodgers GP, Weitz HH; American College of Cardiology Foundation; American Heart Association/; HRS; SCAI; American College of Physicians Task Force on Clinical Competence and Training. ACCF/AHA/HRS/SCAI clinical competence statement on physician knowledge to optimize patient safety and image quality in fluoroscopically guided invasive cardiovascular procedures: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training. Circulation. 2005 Feb 1;111(4):511-32.</citation>
    <PMID>15687141</PMID>
  </reference>
  <reference>
    <citation>Klein LW, Miller DL, Balter S, Laskey W, Haines D, Norbash A, Mauro MA, Goldstein JA; Joint Inter-Society Task Force on Occupational Hazards in the Interventional Laboratory. Occupational health hazards in the interventional laboratory: time for a safer environment. Catheter Cardiovasc Interv. 2009 Feb 15;73(3):432-8. doi: 10.1002/ccd.21801.</citation>
    <PMID>19214981</PMID>
  </reference>
  <reference>
    <citation>Miller DL, Schueler BA, Balter S; National Council on Radiation Protection and Measurements; International Commission on Radiological Protection. New recommendations for occupational radiation protection. J Am Coll Radiol. 2012 May;9(5):366-8. doi: 10.1016/j.jacr.2012.02.006.</citation>
    <PMID>22554637</PMID>
  </reference>
  <reference>
    <citation>Ciraj-Bjelac O, Rehani MM, Sim KH, Liew HB, Vano E, Kleiman NJ. Risk for radiation-induced cataract for staff in interventional cardiology: is there reason for concern? Catheter Cardiovasc Interv. 2010 Nov 15;76(6):826-34. doi: 10.1002/ccd.22670.</citation>
    <PMID>20549683</PMID>
  </reference>
  <reference>
    <citation>Vano E, Kleiman NJ, Duran A, Romano-Miller M, Rehani MM. Radiation-associated lens opacities in catheterization personnel: results of a survey and direct assessments. J Vasc Interv Radiol. 2013 Feb;24(2):197-204. doi: 10.1016/j.jvir.2012.10.016. Epub 2013 Jan 28.</citation>
    <PMID>23369556</PMID>
  </reference>
  <reference>
    <citation>Mahmud E, Naghi J, Ang L, Harrison J, Behnamfar O, Pourdjabbar A, Reeves R, Patel M. Demonstration of the Safety and Feasibility of Robotically Assisted Percutaneous Coronary Intervention in Complex Coronary Lesions: Results of the CORA-PCI Study (Complex Robotically Assisted Percutaneous Coronary Intervention). JACC Cardiovasc Interv. 2017 Jul 10;10(13):1320-1327. doi: 10.1016/j.jcin.2017.03.050.</citation>
    <PMID>28683937</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 20, 2019</study_first_submitted>
  <study_first_submitted_qc>May 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <last_update_submitted>February 8, 2020</last_update_submitted>
  <last_update_submitted_qc>February 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data will be available 12 months after study completion.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT03959072/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

